$ACCV

Rubiera Michael purchased $58K of ACCV (indirect holdings)

Rubiera Michael (Chief Executive Officer) purchased 3,200 indirectly-held shares of Accelevation Holdings Corp. (ACCV) at $18.00 on 2026-10-01.

Original reporting
SEC EDGAR · Rubiera Michael
Published Oct 6, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACCV
Neutral
high confidence
Mentioned
$ACCV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACCVNeutralLow
01

Why it matters

The filing provides a fresh data point on insider sentiment but limited material impact due to small size.

02

Market read

Minor insider purchase with low trading relevance.

03

What to watch

Insider's total holdings remain small; market may discount the trade.

Relevance 4/10Novelty 4/10Timing: post‑filing 2026‑10‑05

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ACCVNeutralHigh confidence
Context

CEO Rubiera Michael bought 3,200 shares at $18 each, total $57,600, increasing his stake to 3,200 shares.

Expected impact

modest upward pressure as market prices in insider buying

Evidence & confidence

The transaction is a primary Form 4 filing, but the amount is low relative to market cap, limiting impact.

Market effects

none

none

none

Counterpoint

The purchase may be routine compensation rather than a strong bullish signal.

Key entities

  • Accelevation Holdings Corp.

    Issuer of the Form 4 filing.

  • Rubiera Michael

    CEO and insider purchaser.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Accelevation's SkyBridge bookings strengthen Bank of America's bullish outlook

Bank of America initiated coverage of Accelevation with a 'buy' rating and $20 price target, citing strong demand for data center equipment. The bank expects adjusted EBITDA to grow at a 56% CAGR from 2026 to 2030, driven by AI infrastructure investments. Accelevation's SkyBridge platform secured $700M in bookings, and the company benefits from a domestic manufacturing footprint and skilled labor.

$ACCVHigh

JPMorgan initiates Accelevation stock with overweight rating

JPMorgan initiated coverage on Accelevation Holdings (NASDAQ:ACCV) with an overweight rating and a $20.00 price target for December 2027, implying 60% upside. The stock trades at $12.38, near its 52-week low. The company reported $726.6M revenue, 29.3% gross margin, and a 1.93 current ratio. JPMorgan cited a $1.1B backlog and modular scaling capabilities as strengths, while noting risks like hyperscaler capex timing and customer concentration.

Med

Accelevation Secures $650 Million Credit Agreement Led By Bank Of America, JPMorgan, Morgan Stanley, KeyBank And PNC

Accelevation Holdings secured a $650 million credit agreement, including a $400 million revolving facility and a $250 million Term Loan A, both maturing in 2031. The new financing reduces borrowing rates and strengthens the company's balance sheet, according to the company. Bank of America, JPMorgan, Morgan Stanley, KeyBank, and PNC were involved in the agreement.